FCGR1A and Miyoshi myopathy: To address the relationship between the characteristic components of the MM2 (CD64 high) phenotype and disease stage, granulocytic and monocytic markers of MM patients and plasma markers of myeloid activation were stratified by the revised and updated International Staging System (R-ISS) criteria with R-ISS stage III indicative of advanced disease (Figure 6 and Supplemental Figure 12).